Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection

被引：0
|
作者：
Chen, Yiwen [1 ]
Shen, Yan [1 ]
Zhang, Min [1 ]
Wu, Jian [1 ]
Gao, Shunliang [1 ]
Que, Risheng [1 ]
Yu, Jun [1 ]
Tang, Xiaofeng [1 ]
Bai, Xueli [1 ]
Liang, Tingbo [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：571 / 571
页数：1
相关论文
共 50 条
  • [31] Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy
    Chen, Wei
    Hu, Shuifang
    Liu, Zelong
    Sun, Yukun
    Wu, Jian
    Shen, Shunli
    Peng, Zhenwei
    HEPATOLOGY INTERNATIONAL, 2023, 17 (02) : 406 - 416
  • [32] Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases
    Liu, Jianwei
    Xue, Hui
    Bai, Shilei
    Wang, Jie
    Zhang, Yue
    Liu, Liu
    Zhang, Lei
    Yang, Zhao
    Wang, Kui
    HELIYON, 2022, 8 (11)
  • [33] Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation
    Yopp, Adam Charles
    Cheng, Ann-Lii
    Kaseb, Ahmed Omar
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S19 - S19
  • [34] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
    Knox, J.
    Cheng, A.
    Cleary, S.
    Galle, P.
    Kokudo, N.
    Lencioni, P.
    Park, J.
    Zhou, J.
    Mann, H.
    Morgan, S.
    Liu, X.
    Chin, S.
    Vlahovic, G.
    Fan, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Zheng, Jinfang
    Fu, Changbo
    Xu, Guohui
    Bai, Yannan
    Wu, Changxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS632 - TPS632
  • [36] Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study.
    Zhang, Bin
    Jin, Renan
    Xu, Junjie
    Chen, Ming Yu
    Chen, Jiang
    Zhu, Hepan
    Cao, Jiasheng
    Song, Chao
    Yang, Zaibo
    Zhang, Yewei
    Liang, Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 505 - 505
  • [37] Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
    Cai, Mingyue
    Huang, Wensou
    Huang, Jingjun
    Shi, Wenbo
    Guo, Yongjian
    Liang, Licong
    Zhou, Jingwen
    Lin, Liteng
    Cao, Bihui
    Chen, Ye
    Zhou, Juan
    Zhu, Kangshun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection
    Yan, S.
    Zhang, Y.
    Bi, X.
    Zhao, J.
    Du, S.
    Huang, Z.
    Zhang, Y.
    Liu, D.
    Li, Z.
    Zhou, J.
    Cai, J.
    Zhao, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
    Zou, Xinhua
    Xu, Qingyu
    You, Ran
    Yin, Guowen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 267 - 279
  • [40] Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
    Xu, Yongkang
    Fu, Shumin
    Liu, Kan
    Mao, Ye
    Wu, Jianbing
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 853 - 863
12345